Evidence map›Paper›PMID 39272568›Full record

ArticleFoods (Basel, Switzerland)2024

Rice (

Leila Asadollahi, Soheil Abbaspour-Ravasjani, Kyung Ah Kim, Maryam Maghsoodi, Hamed Hamishehkar, Morteza Kosari-Nasab, Ki Hyun Kim

Abstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluation ofPlants (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leila AsadollahiBiotechnology Research Center, Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51368, Iran.ORCID 0000-0002-5919-2460
Soheil Abbaspour-RavasjaniDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51368, Iran.ORCID 0000-0001-7541-1638
Kyung Ah KimSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Maryam MaghsoodiDepartment of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
Hamed HamishehkarDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
Morteza Kosari-NasabDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 51368, Iran.ORCID 0000-0001-8454-5873
Ki Hyun KimSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0002-5285-9138

Funding

National Research Foundation of Korea 2019R1A5A2027340 and 2021R1A2C2007937
6 · The paper itself

Abstract

Rice is one of the plants proven to possess antioxidant, anti-inflammatory, anti-proliferative, and whitening properties, making it one of the most beneficial plants in this regard. This study aimed to introduce a novel natural cosmetic and pharmaceutical product based on rice callus as a source of active ingredients that can inhibit skin melanoma cell (B16F10) proliferation and brighten the skin. The 2,4-D hormone at concentrations of 1 µg/mL and 1.5 µg/mL was used to induce rice callus formation. Rice callus extracts were then prepared using aqueous and ethanolic solvents, with a concentration of 1 mg/mL used for characterization tests. To determine the optimal hormone concentration, the phenols/flavonoids, antioxidant activity, proteins, and carbohydrates in the extracts were measured. The optimal concentration of the hormone was found to be 1 µg/mL. Finally, the anti-melanocyte and skin-whitening activity of the extracts was assessed through measurements of their cytotoxicity and inhibition of melanin synthesis-related enzymes. Cellular cytotoxicity measurements revealed that the ethanolic extract induced more cytotoxicity than the aqueous extract, with IC

Indexed as

antioxidant activitycosmeceuticalscytotoxicitymelanoma inhibitionrice callustyrosinasewhitening

Identifiers

PMID39272568
PMCPMC11394965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.